Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

Reducing Sodium in Narcolepsy Treatment: Cardiovascular Insights From the XYLO Trial

by Neurology Live
0 Comments
0 Mins
Richard Kovacs, MD, PhD, chief medical officer for the American College of Cardiology, discusses interim XYLO trial results, highlighting how switching to low-sodium oxybate can significantly impact blood pressure and cardiovascular risk profiles in narcolepsy.
Tags:
Neurology Live
Author

Neurology Live

Previous Post
STAT+: Duke scientists seemed to have developed a ‘Holy Grail’ of cancer treatment. Then the truth came out
Next Post
Reprieve Cardiovascular Raises $61M to Fund Pivotal Heart Failure Trial
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago